Peptide record

TPDB07398

Antibacterial Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07398
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia PD_Hemolysis
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, and PD_Hemolysis, with an available 3D structural model.
Sequence
GLLSLLSLLGKAL
Physicochemical Analysis
C61H112N14O16
RNDCEQHIMFPTWYV
L
1297.64
10.10
1
0
8
+1
-2.82
1.700
217.69
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
2
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
2
G
0
H
0
I
7
L
1
K
0
M
0
F
0
P
2
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 7 K: 1 M: 0 F: 0 P: 0 S: 2 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
13
C61H112N14O16
1297.64
10.10
+1
-2.82
1.700
Evidence Records 5 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.78 µM

Target

Staphylococcus aureus USA300

Source & Reference

NA

Other

Active against S. aureus USA300 (MIC 0.78 uM), P-aeruginosa PAO1 (MIC > 25 uM), E. coli ATCC 25922 (MIC 3.1 uM), and K. pneumonia ATCC1
Evidence 2 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

Escherichia coli ATCC 25922

Source & Reference

NA

Other

Active against S. aureus USA300 (MIC 0.78 uM), P-aeruginosa PAO1 (MIC > 25 uM), E. coli ATCC 25922 (MIC 3.1 uM), and K. pneumonia ATCC13883 (MIC 3.1 uM).
Evidence 3 Activity

Activity

MIC
Antibacterial
3.1 µM

Target

K. pneumonia ATCC13883

Source & Reference

NA

Other

A300 (MIC 0.78 uM), P-aeruginosa PAO1 (MIC > 25 uM), E. coli ATCC 25922 (MIC 3.1 uM), and K. pneumonia ATCC13883 (MIC 3.1 uM).
Evidence 4 Activity

Activity

50% Hemolysis
Toxicity
4 µM
Hemolytic Cytotoxic
50% Hemolysis | 4 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Low cationicity is important for systemic in vivo efficacy of database-derived peptides against drug-resistant Gram-positive pathogens. | Proc Natl Acad Sci U S A | 2019
Evidence 5 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis